Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study

被引：21
|
作者：
Modi, S.
Tsurutani, J.
Tamura, K.
Park, H.
Sagara, Y.
Murthy, R.
Iwata, H.
Krop, I. E.
Doi, T.
Redfern, C.
Moreno-Aspitia, A.
Redman, R.
Lee, C.
Sugihara, M.
Fujisaki, Y.
Takahashi, S.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Natl Canc Ctr Hosp East, Chiba, Japan
[10] Sharp HealthCare, San Diego, CA USA
[11] Mayo Clin, Jacksonville, FL 32224 USA
[12] Univ Louisville, Louisville, KY 40292 USA
[13] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[14] Daiichi Sankyo Co Ltd, Tokyo, Japan
[15] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer
    Iwasa, Satoru
    Shitara, Kohei
    Takahashi, Shunji
    Park, Haeseong
    Kadowaki, Shigenori
    Modi, Shanu
    Nonagase, Yoshikane
    Tamura, Kenji
    Yamaguchi, Kensei
    Muro, Kei
    Tsurutani, Junji
    Shahidi, Javad
    Lee, Caleb C.
    Sugihara, Masahiro
    Kawaguchi, Yoshinori
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [4] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [5] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
    Iwata, Hiroji
    Tamura, Kenji
    Doi, Toshihiko
    Tsurutani, Junji
    Modi, Shanu
    Park, Haeseong
    Krop, Ian E.
    Sagara, Yasuaki
    Redfern, Charles H.
    Murthy, Rashmi Krishna
    Redman, Rebecca A.
    Shitara, Kohei
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer
    Andrikopoulou, Angeliki
    Zografos, Eleni
    Liontos, Michalis
    Koutsoukos, Konstantinos
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    CLINICAL BREAST CANCER, 2021, 21 (03) : E212 - E219
  • [9] Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
    Takahashi, Shunji
    Modi, Shanu
    Tsurutani, Junji
    Krop, Ian E.
    Iwata, Hiroji
    Wada, Russell
    Yin, Ophelia
    Garimella, Tushar
    Sugihara, Masahiro
    Zhang, Lin
    Lee, Caleb
    Saito, Kaku
    Kawasaki, Yui
    Yver, Antoine
    Tamura, Kenji
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2019, 30
12345